Table 2. Summary of the meta-analysis depicting the association between dosimetric factors and risk of RP≥ grade 2 after SBRT in lung cancer.

Dose-volume parameters	Studies (n)	Statistical method	Heterogeneity		Effect Estimate
			P	I2 (%)
Age	4	Mean Difference (IV, Fixed, 95% CI)	1.00	0	-0.25 [-6.15, 5.65]
PTV	5	Mean Difference (IV, Fixed, 95% CI)	0.46	0	27.71 [14.43, 40.99]
MLD	3	Mean Difference (IV, Fixed, 95% CI)	0.004	81	4.79 [1.28, 8.30]
Total MLD	5	Mean Difference (IV, Fixed, 95% CI)	0.83	0	1.66 [0.99, 2.33]
V5	4	Mean Difference (IV, Fixed, 95% CI)	0.74	0	13.44 [7.50, 19.39]
V10	4	Mean Difference (IV, Fixed, 95% CI)	0.92	0	8.58 [5.50, 11.66]
V20	4	Mean Difference (IV, Fixed, 95% CI)	0.88	0	4.56 [3.07, 6.04]
V40	3	Mean Difference (IV, Fixed, 95% CI)	0.18	41	1.06 [0.56, 1.55]
PTV: ≤145 cc vs. >145 cc	4	Odds Ratio (IV, Fixed, 95% CI)	0.48	0	2.85 [2.70, 3.01]
Total MLD: <4.70 Gy vs. ≥4.70 Gy	4	Odds Ratio (IV, Fixed, 95% CI)	0.54	0	4.01 [3.01, 5.33]
V5: <26.80% vs. ≥26.80%	4	Odds Ratio (IV, Fixed, 95% CI)	0.4	0	5.05 [2.92, 8.74]
V10: ≤12% vs. >12%	4	Odds Ratio (IV, Fixed, 95% CI)	0.27	24	4.42 [2.49, 7.84]
V20: <5.80% vs. ≥5.80%	3	Odds Ratio (IV, Fixed, 95% CI)	0.48	0	5.22 [2.47, 10.99]